RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 8 filers reported holding RUBIUS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $4 | -100.0% | 22,226 | 0.0% | 0.00% | – |
| Q3 2022 | $10,000 | -47.4% | 22,226 | +0.4% | 0.00% | – |
| Q2 2022 | $19,000 | -88.1% | 22,147 | -23.3% | 0.00% | -100.0% |
| Q1 2022 | $159,000 | -45.4% | 28,886 | -4.0% | 0.00% | -50.0% |
| Q4 2021 | $291,000 | -64.2% | 30,096 | -33.8% | 0.00% | -50.0% |
| Q3 2021 | $813,000 | +30.1% | 45,491 | +77.7% | 0.00% | +33.3% |
| Q2 2021 | $625,000 | -23.1% | 25,606 | -16.5% | 0.00% | -25.0% |
| Q1 2021 | $813,000 | +230.5% | 30,665 | -5.3% | 0.00% | +300.0% |
| Q4 2020 | $246,000 | +241.7% | 32,365 | +125.7% | 0.00% | – |
| Q3 2020 | $72,000 | -71.7% | 14,338 | -66.2% | 0.00% | -100.0% |
| Q2 2020 | $254,000 | +66.0% | 42,439 | +23.3% | 0.00% | +100.0% |
| Q1 2020 | $153,000 | -5.6% | 34,431 | +102.4% | 0.00% | 0.0% |
| Q4 2019 | $162,000 | +4.5% | 17,009 | -13.9% | 0.00% | 0.0% |
| Q3 2019 | $155,000 | +32.5% | 19,746 | +205.6% | 0.00% | 0.0% |
| Q1 2019 | $117,000 | – | 6,462 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,618,351 | $13,118,000 | 65.48% |
| Flagship Pioneering Inc. | 38,296,526 | $191,866,000 | 5.30% |
| Abbot Financial Management, Inc. | 563,500 | $2,823,000 | 1.83% |
| HARBOURVEST PARTNERS LLC | 986,878 | $4,944,000 | 1.83% |
| Artal Group S.A. | 3,778,913 | $18,932,000 | 0.46% |
| Virtus ETF Advisers LLC | 50,863 | $255,000 | 0.13% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 402,555 | $2,017,000 | 0.02% |
| PDT Partners, LLC | 49,500 | $248,000 | 0.02% |
| Baillie Gifford | 4,273,861 | $21,413,000 | 0.02% |
| Trexquant Investment LP | 36,363 | $182,000 | 0.01% |